FELICITAS MAVUNGA: Open Payments
NPI 1871957340 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$542 in 26 payments from 13 companies in 2025. Trend: 2023 $250 · 2024 $206 · 2025 $542
Food & beverage: $542
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Lundbeck LLC | 3 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $61 |
| Alkermes, Inc. | 3 | $61 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 2 | $37 |
| Corium, LLC | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
Products named: REXULTI, CAPLYTA, ARISTADA, Auvelity, TRINTELLIX, Jornay PM, Xelstrym, ABILIFY ASIMTUFII.
Industry payments across NE — which companies pay providers there.
